This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1273 entries already.
As part of the green transformation of North Rhine-Westphalia’s former coal-mining region, independent assessors have recommended the co-financing of two biotechnology processes developed at pilot scale by Evonik Industries AG, with the aim of advancing them to demonstration scale. The third funding round of the “Produktives.NRW” call includes approximately €70 million from the EU’s Just Transition Fund (JTF) allocated to six projects.
Basel-based NUCLIDIUM AG has successfully closed a Series B financing round of CHF 79 million (EUR 84 million) to advance the development of its copper-based radiopharmaceutical platform. The round was led by Kurma Growth Opportunities Fund, Angelini Ventures, Wellington Partners, and Neva SGR, a company of the Intesa Sanpaolo Group.
The biotech company Actithera, with locations in Cambridge, USA, and Oslo, Norway, has successfully closed a major Series A round, raising US $75.5 million. Its isotope-agnostic platform — designed with a specific focus on the interaction between linker and target molecule — has attracted strong interest from a wide range of investors. However, the path to this achievement was not as straightforward as anticipated, CEO Andreas Goutopoulos told European Biotech News.
French biotech Ciloa SAS has received a €6.5m grant to advance its adiponectin-loaded exosome candidate, APN-sEV, into Phase I safety trials, ahead of efficacy evaluation in indications including type 2 diabetes, obesity, and liver fibrosis.
After Finnish protein powder producer Solarfoods signed a strategic agreement with two US food manufacturers to supply 6,000 tonnes of Solein from 2030 onwards, the company has now announced a more concrete partnership with US flavour manufacturer Sensapure Flavours Inc.
The European Commission last week unveiled its Life Sciences Strategy, which aims to elevate Europe’s biotechnology sector from third to first place globally by 2030, backed by an investment of €10bn. These funds are to be reallocated to food, agricultural, pharmaceutical and industrial biotechnology sectors.
Biosimilar major Sandoz has started construction of an additional US$440m biosimilar facility near Ljubljana and it set to expand its investment footprint in Slovenia by US$1.1bn.
California oral macrocyclic peptide specialist Unnatural Products, Inc. and Dutch-Belgian Argenx SE have formed a multi-target research collaboration aimed at developing oral macrocyclic peptide drugs with UNP’s synthetic macrocycle platform.
CDMO and filled syringe specialist Vetter has broken the ground for a new clinical site construction in the greater Chicago area that is expected to be ready for early clinical filling by the end of 2029.
Portuguese fibre producer Altri SGPS S.A.has signed an agreement to acquire a majority interest in Swiss clean technology company AeoniQ to support the commercial-scale development of the first fully biodegradable cellulose-based filament designed to replace polyester and nylon.